MedX Health Corp.
(TSX-V: MDX)
- Commercialized a regulatory-approved highly effective skin cancer scanning device
- Provides images that can be uploaded on the company’s proprietary cloud-based tele-health platform and sent to local dermatologists for assessment
- Patients can receive their prognosis and receive treatment within 72 hours after the initial screening
- Immanent expansion into Mexico, Colombia and USA
- Strong relationship with a Canadian national pharmacy chain with ~1,500 stores across the country
- Initial orders from its Brazilian distribution partner that could result in $8 million of hardware sales over the next 2 years and a run-rate of $14 million of high margin, recurring platform revenue by the end of FY21
- Dermatologists have declared these images the “next best thing to being there†in person
- Platform has been proven through a proof-of-concept trial in Norway (109 Boots pharmacies captured 80,000 scans and found 800 cases of melanoma)
- Company reported revenue of $860,248 for the year ended December 31, 2019
Does This Product Satisfy A Need?
- Skin cancer accounts for one-third of all cancer cases and is one of the only forms of cancer that is increasing in prevalence
- Early detection can result in a survival rate of 98%
- If left undetected, skin cancer and melanoma in particular, metastasizes very quickly, dropping the survival rate down to 25%
- Rigorous and regular screening regiment now more important than ever
Products
MedX’s SIAscope captures images ‘2mm’ below the skin’s surface
- Only technology that can capture images below the skins surface
- The SIAscope is placed directly on the suspicious mole allowing no ambient light to distort the image
- The fixed focal point and controlled light wavelengths allow for a perfect Dermascopic image as well as 4 additional images
- The SIAscope is the only scanner in the world that can achieve this
MedX Health Corp. is an advertising client of AGORA Internet Relations Corp.
Tags: DermSecure, MedX, MoleMate, Simsys, Skin Cancer